Notícias

SELLAS Life Sciences Group, Inc. reported second-quarter 2026 results showing a net loss of US$9.61 million and basic loss per share from continuing operations of US$0.05, with first-half 2026 net loss reaching US$18.01 million and basic loss per share of US$0.10. Despite wider net losses in dollar terms, the company’s loss per share narrowed year on year, pointing to the impact of share count changes amid heightened interest in its Phase 3 GPS cancer vaccine program following positive...

SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts...

SELLAS Life Sciences Group stock has posted a very large 3 year return while the latest valuation checks flag it as expensive rather than a clear bargain. Over the past 3 years, SELLAS Life Sciences Group has delivered a gain of about 7.9x, which sets a high bar for any further upside to be justified. Progress toward key milestones in the REGAL AML trial and the advancement of SLS009 in difficult cancer indications can support high growth expectations, yet the usual risks around clinical...

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

Maxim Group described Moderna’s positive late-stage melanoma results as a “win for cancer vaccines,” arguing the surge in Moderna shares should support SELLAS if its key trial succeeds.

A separate pediatric study delivered “striking” WT1 vaccine results, supporting GPS’s scientific rationale, the company's CEO said.

Stergiou highlighted a Phase 2 study published in the Blood Advances journal that evaluated a maintenance therapy in 17 children with hard-to-treat acute leukemia following stem-cell transplants.

Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.

Vanguard held SLS and IBRX positions worth a combined $259 million at quarter-end.

Alliance Global lifted its SLS price target to $35 from $25, implying nearly 200% upside, and maintained a ‘Buy’ rating.

Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.

The biotech, focused on novel cancer therapies, reported a net loss of $9.6 million, or $0.05 per share, for the quarter ended June 30.

Wall Street expects no quarterly revenue and a GAAP loss of $0.04 per share, narrowing from $0.05 previously.

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

In recent months, Daiwa Securities very sharply increased its stake in SELLAS Life Sciences Group by 100,300 shares, while SELLAS reported that its Phase 3 REGAL trial in acute myeloid leukemia had reached 78 of the 80 events required for final analysis and held an estimated US$138.30 million in cash at the end of June. This combination of an imminent pivotal trial readout and a strengthened institutional presence highlights how clinical and balance-sheet milestones are converging for...

SELLAS Life Sciences Group (SLS) is back in focus as its Phase 3 REGAL trial in acute myeloid leukemia nears final analysis and Daiwa Securities reports a very large increase in its shareholding. See our latest analysis for SELLAS Life Sciences Group. The recent clinical update and Daiwa’s larger stake come after a sharp move in SELLAS Life Sciences Group’s share price, with a 1-day share price return of 12.09% and a year-to-date share price return of 157.93%, while the 1-year total...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet its recent share price swings and a low overall value score suggest the stock may now be pricing in a lot of optimism. The stock has returned about 6.1x over the past 3 years, which sets a high bar for any further upside to be justified by fundamentals. Future clinical and commercial progress can support the current valuation, but execution risk and funding needs typical for early stage biopharma may limit how much...

Vontobel cut its holding by 16% but retained SLS shares worth $2.17 million.

Opus Capital held 385,604 shares worth about $5.69 million after increasing its position by 11.3%.

A new Schedule 13G filing showed Vanguard Capital Management owned 9.67 million SLS shares as of June 30, 2026.

New York State Common Retirement Fund boosted its holding by 70%, while Commonwealth and Axxcess each raised stakes by about 17%.

An arbitrator recently dismissed Sellas’ claims against 3D Medicines and ordered about $1 million in legal-cost payments.

Sellas estimated cash and cash equivalents of $138.3 million as of June 30.

CEO Angelos Stergiou said recently on “FOX & Friends” that AI and precision medicine could speed drug development and improve patient selection.

During an interview on Fox & Friends on Friday, Stergiou said AI will play a major role in helping cure cancer by enabling more precise treatments.

A new MD Anderson study found that survival was significantly shorter among older and higher-risk AML patients.

Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.

Sellas is preparing for database lock, potential BLA-related regulatory work, and development of SLS009, its second AML drug.

The company entered a quiet period for trial-specific updates ahead of topline data.

Investors named Johnson & Johnson, Merck, Pfizer, AbbVie, Eli Lilly and Bristol Myers as possible bidders.